cladribine,lintuzumab,Cytarabine,Filgastrim,Mitoxantrone
merck,seagen,amgen
['equate', 'leusm', 'venetoclax', '225ac', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'lintuzumab', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'dance', '2019', 'cladribine']
#ash22 #leusm abedin: lintuzumab (anti-cd33 conjugated to act225, delivers alpha particle short range radiotherapy which doesn t req shielding or other precautions) in combo w clag-m in rr aml. dose escalation of lintu. 74% eln adverse risk, med prior tx 2 lines, 57% prior allo. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)